Dania Pagarkar joins Ethics Talk to discuss her article, coauthored with Drs Erin Harrop and Lisa Erlanger: “How Should We Approach Body Size Diversity in Clinical Trials?”
Introduction of an intervention that reduces the perceived risk of a given behavior may cause a person to increase risky behavior—this is called “risk compensation.”
Preventing bad outcomes for teens and their offspring was the impetus behind confidential care for reproductive health. Requiring parental involvement created an obstacle to the provision of necessary care.
Michael Farias, MD, MS, MBA and Rahul H. Rathod, MD
A distinguishing feature of a SCAMP is its ability to capture knowledge-based diversions from a recommended pathway and to “learn” from such individualized patient management.
The only studies in which hGH was shown to have a positive effect on athletic performance were in anabolic steroid users, so testing for hGH alone may not be accomplishing the intended goal.
Donna T. Chen, MD, MPH, Lois Shepherd, JD, and Daniel M. Becker, MD, MPH, MFA
When most statutes about confidential treatment of adolescents were adopted, immunization against sexually transmitted infection was not anticipated, so the statutes contain no specific inclusion of such preventive measures.
As physicians we decide which tests or treatments go on the bill but have little idea how our decisions impact what patients pay. Now patients, payers, and policymakers are demanding that we consider the cost of our recommendations.
Physician employment adds a practice management stakeholder to the patient-physician encounter, a stakeholder whose financial interests differ from those of physicians in solo or group practice.